C
CorFlow Therapeutics
The first combined diagnostic and therapeutic medical device for improving microvascular obstructions after a heart attack
About CorFlow Therapeutics
CorFlow Therapeutics AG is a Swiss-based medical device company that develops solutions for heart attack patients with microvascular obstruction (MVO). The company's flagship product is the CorFlow Controlled Flow Infusion System, a technology designed to diagnose and treat MVO in the catheterization laboratory.
Read full description
CorFlow's business model revolves around the development and commercialization of its proprietary medical devices. The company targets cardiologists and healthcare institutions as its primary clients. By providing a novel approach to treating MVO, CorFlow aims to improve patient outcomes and reduce the economic burden of cardiovascular diseases. The company has secured significant funding from venture capital firms, which will be used to advance its clinical programs and prepare for market entry.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Baar, Switzerland
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 91.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT MedTech
- Business model
- Manufacturing, SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2024 | $48M | $194M | Wellington Partners · KOFA Healthcare Investments · Unorthodox ventures · Mérieux Equity Partners | ↗ |
| SERIES AOther financing | Mar 2021 | $7.3M | $29M | 415 Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for CorFlow Therapeutics is 1.1K monthly website visits, up 1122.2% over the last three months. CorFlow Therapeutics's team grew 15.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- AQArshad Quadri
- DLDr. Jean-Claude Laborde
Innosuisse
Series A10 investors entered at this stage
415 Capital
Panakès Partners
Broadview Ventures
Wellington Partners- KIKOFA Healthcare Investments
Unorthodox ventures
Mérieux Equity Partners
Monte Carlo Capital- LFLaerdal million lives fund
M&L Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CorFlow Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CorFlow Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.